Tandem Diabetes Care Inc Cash Flow Conversion Efficiency
Tandem Diabetes Care Inc cash flow conversion efficiency. Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.58 Million) by net assets ($130.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tandem Diabetes Care Inc (2011–2025)
Cash flow conversion efficiency of Tandem Diabetes Care Inc from 2011 to 2025. This chart illustrates how Tandem Diabetes Care Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Tandem Diabetes Care Inc for real-time trading data and today's change.
Tandem Diabetes Care Inc Cash Flow Conversion Ratio Explained
Tandem Diabetes Care Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tandem Diabetes Care Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tandem Diabetes Care Inc ranked by their cash flow conversion efficiency. Also see Tandem Diabetes Care Inc (TNDM) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gravita India Limited
NSE:GRAVITA
|
-0.021x |
|
Beijing Toread Outdoor Product
SHE:300005
|
0.002x |
|
United States Steel Corp
BA:X
|
-0.033x |
|
RPC Inc
NYSE:RES
|
0.039x |
|
Sichuan Chengfei Integration Technology Corp Ltd
SHE:002190
|
0.034x |
|
Ami Organics Limited
NSE:AMIORG
|
0.006x |
|
Inner Mongolia ERDOS Resources Co Ltd B
SHG:900936
|
0.075x |
|
TRUSTPILOT GROUP LS -01
F:6VZ
|
N/A |
Annual Cash Flow Conversion Efficiency for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Tandem Diabetes Care Inc from 2011 to 2025. Review how much free cash does Tandem Diabetes Care Inc generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $155.17 Million | $-9.72 Million | -0.063x | -168.04% |
| 2024-12-31 | $263.10 Million | $24.23 Million | 0.092x | +190.78% |
| 2023-12-31 | $313.63 Million | $-31.81 Million | -0.101x | -188.42% |
| 2022-12-31 | $439.95 Million | $50.46 Million | 0.115x | -55.39% |
| 2021-12-31 | $433.11 Million | $111.36 Million | 0.257x | +281.78% |
| 2020-12-31 | $366.31 Million | $24.67 Million | 0.067x | -68.67% |
| 2019-12-31 | $194.98 Million | $41.91 Million | 0.215x | +439.16% |
| 2018-12-31 | $131.28 Million | $-8.32 Million | -0.063x | -102.79% |
| 2017-12-31 | $-29.15 Million | $-66.14 Million | 2.269x | -78.02% |
| 2016-12-31 | $-5.93 Million | $-61.17 Million | 10.321x | +1214.73% |
| 2015-12-31 | $63.47 Million | $-58.76 Million | -0.926x | +17.68% |
| 2014-12-31 | $54.57 Million | $-61.38 Million | -1.125x | -172.10% |
| 2013-12-31 | $115.54 Million | $-47.76 Million | -0.413x | -230.97% |
| 2012-12-31 | $-106.05 Million | $-33.47 Million | 0.316x | +4.43% |
| 2011-12-31 | $-71.29 Million | $-21.55 Million | 0.302x | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more